Cinclus Pharma: The gem hidden in plain sight - Redeye

Redeye initiates coverage of Cinclus Pharma, a Swedish biotech company offering a next-generation solution to the USD+5bn GERD treatment market. Building on its superior efficacy, a robust safety profile and being on the brink of pivotal studies, the lead candidate linaprazan glurate has a clear-cut pathway to the market. Bolstered by a strong management and a newly secured financial runway, we see a case with blockbuster potential.

Länk till analysen i sin helhet: https://www.redeye.se/research/1040317/cinclus-pharma-the-gem-hidden-in-plain-sight?utm_source=finwire&utm_medium=RSS